Maximum quantity allowed is 999
请选择数量
CAS RN: 130929-57-6 | 產品號碼: E0961
| 產品號碼 | E0961 |
純度/分析方法 
|
>98.0%(T)(HPLC) |
| 分子式 / 分子量 | C__1__4H__1__5N__3O__5 = 305.29 |
| 外觀與形狀（20°C） | Solid |
| 儲存條件
|
Refrigerated (0-10°C) |
| 儲存在惰性氣體下 | Store under inert gas |
| 應避免的情況 | Air Sensitive,Heat Sensitive |
| 包裝和容器
|
1G-Glass Bottle with Plastic Insert （閲覽圖片） |
| CAS RN | 130929-57-6 |
| Reaxys-RN | 8158723 |
| PubChem Substance ID | 468591677 |
| Merck Index(14) | 3594 |
| MDL編號 | MFCD00866580 |
產品規格
| Appearance | White to Yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Volumetric Analysis) | min. 98.0 % |
| Melting point | 160.0 to 164.0 °C |
| NMR | confirm to structure |
性質
| 熔點 | 162 °C |
| 水溶性 | Insoluble |
| 溶解性（微溶於） | Methanol |
GHS
相關法規
| RTECS # | UC6316195 |
運輸資料
| HS編碼* | 2926.90-000 |
Application
Entacapone: A Selective and Reversible Inhibitor of Catechol-O-methyltransferase (COMT)
Entacapone and tolcapone [T3856] are selective and reversible inhibitors of catechol-O-methyltransferase (COMT) which is one of several enzymes that degrade catecholamines (such as L-DOPA [D0600], dopamine [A0305], L-epinephrine [A0173], and norepinephrine [A0906]).1,2) COMT catalyzes the transfer of the methyl group of S-adenosyl-L-methionine to the phenolic group of substrates that contain a catechol structure including catecholamines. Entacapone and tolcapone cross the blood-brain barrier and can inhibit both peripheral and central COMT activity. Therefore, it has been suggested that entacapone and tolcapone prolong the biological half-life of L-DOPA and the therapeutic effect of L-DOPA for Parkinson's disease patients. Indeed, entacapone is currently in wide clinical use, while tolcapone can be used in restricted indications only, due to its hepatotoxicity.3) (The product is for research purpose only.)
References
- 1) Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone
- 2) Catechol-O-methyltransferase and its inhibitors in Parkinson's disease (a review)
- 3) Clinical advantages of COMT inhibition with entacapone - a review
- 4) High-performance liquid chromatography method for the quantification of entacapone in human plasma
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。